Alliqua to Explore Business Development Efforts for Hydrogel Transdermal Delivery Platform in the Cosmeceutical Industry
NEW YORK, Nov. 19, 2012 /PRNewswire/ -- Alliqua, Inc. (OTCQB:ALQA) ("Alliqua" or the "Company"), a biopharmaceutical company focused on the development, manufacturing and distribution of proprietary transdermal wound care and drug delivery technologies, today announced the Company's exploration of business development efforts for its proprietary transdermal delivery platform in the cosmeceutical industry.
According to market research data from the Freedonia Group, the cosmeceutical market reached $6.4 billion in 2010 and is projected to grow to $8.5 billion by 2015, largely fueled by consumers searching to stave off the physical signs of aging. While this market has traditionally been focused on consumers aged 45 and older, recent trends show younger consumers are seeking out anti-aging products designed to prevent or treat even early signs of aging including fine lines and wrinkles. Alliqua believes its transdermal platform is ideal for administering the key ingredients of these anti-aging products more effectively to targeted areas of the body. In doing so, the Alliqua technology has the potential to greatly enhance the performance of a variety of cosmeceutical products across a broad spectrum of areas. Additionally, the time to market for cosmeceutical products is typically much shorter than for traditional drug delivery making it a very attractive business opportunity for Alliqua.
James Sapirstein , CEO of Alliqua stated, "The cosmeceutical industry represents a vast market opportunity for our proprietary transdermal platform. What is equally as exciting for Alliqua is that with our hydrogel technology, we can reach the market in a relatively short time frame when compared to traditional drug delivery platforms. We intend to aggressively pursue partnerships with various manufacturers to help them increase the effectiveness of their products and achieve more optimal results for the consumer. By doing this we have the potential to build a highly profitable business segment for Alliqua in the cosmeceutical marketplace."
About Alliqua, Inc.
Alliqua, Inc. (ALQA) ("Alliqua") is a biopharmaceutical company focused on the development, manufacturing and distribution of our proprietary transdermal wound care and drug delivery technologies. Alliqua's leading technology platform produces hydrogels, a 3-dimensional cross-linked network of water soluble polymers capable of numerous chemical configurations.
Alliqua currently markets its new line of 510K FDA approved hydrogel products for wound care under the SilverSeal® brand. The Company's electron beam production process located at its 16,000 square foot GMP manufacturing facility in Langhorne, PA, allows Alliqua to aggressively develop and custom manufacture a wide variety of hydrogels. Alliqua's hydrogels can be customized for various transdermal applications to address market opportunities in the treatment of wounds as well as the delivery of numerous drugs or other agents for the pharmaceutical and cosmetic industries. Additionally, the Company's drug delivery platform, in combination with certain drugs, provides pharmaceutical companies with potential greater patient compliance and could potentially extend the life of valuable drug patents.
Any statements contained in this press release regarding our ongoing research and development and the results attained by us to-date have not been evaluated by the Food and Drug Administration.
Legal Notice Regarding Forward-Looking Statements
This release contains forward-looking statements. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties outside of the our control that can make such statements untrue, including, but not limited to, inadequate capital, adverse economic conditions, intense competition, lack of meaningful research results, entry of new competitors and products, adverse federal, state and local government regulation, termination of contracts or agreements, technological obsolescence of our products, technical problems with our research and products, price increases for supplies and components, inability to carry out research, development and commercialization plans, loss or retirement of key executives and research scientists and other specific risks. We currently have no commercial products intended to diagnose, treat, prevent or cure any disease. The statements contained in this press release regarding our ongoing research and development and the results attained by us to-date have not been evaluated by the Food and Drug Administration. There can be no assurance that further research and development, and/or whether clinical trial results, if any, will validate and support the results of our preliminary research and studies. Further, there can be no assurance that the necessary regulatory approvals will be obtained or that we will be able to develop new products on the basis of our technologies. In addition, other factors that could cause actual results to differ materially are discussed in our Annual Report on Form 10-K filed with the SEC on March 29, 2012 and our most recent Form 10-Q filings with the SEC. Investors and security holders are urged to read these documents free of charge on the SEC's web site at www.sec.gov. We undertake no obligation to publicly update or revise our forward-looking statements as a result of new information, future events or otherwise.
SOURCE Alliqua, Inc.
More by this Source
Letter from Alliqua CEO, Dave Johnston, to Shareholders
Mar 07, 2013, 07:00 ET
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.